Serum glial fibrillary acidic protein (sGFAP) is quickly maturing as a biomarker to predict disability in patients with multiple sclerosis (MS), but it will add information to, not compete with, serum neurofilament light chain (sNFl) levels, according to multiple independent studies.
sNFl and sGFAP Predict MS Disability in ... - My MSAA Community
sNFl and sGFAP Predict MS Disability in Unique Ways
Written by
BettysMom
To view profiles and participate in discussions please or .
7 Replies
•
Thanks for posting.
Interesting! Thanks for sharing BettysMom !
i have asked both my neurologist and an ms specialist i saw about sNFl and they both said it was in the research stage and they had no interest in it for now. they made me feel silly for even mentioning it.
Shame on them. They failed to appreciate that YOU have a right to be interested even if they aren't.
Not what you're looking for?
You may also like...
Novel Agent First to Slow Disability in Nonrelapsing Secondary MS
A new investigational drug has become the first agent to slow disability in patients with...
Smoldering MS May Warrant Unique Diagnosis, Treatment, and Research Strategies
Smoldering-associated worsening (SAW) of multiple sclerosis (MS) deserves a broader, more...
Shift Needed in Research, Treatment, Care for Aging MS Population
NASHVILLE, Tennessee — For the first time, the majority of patients with multiple sclerosis (MS)...
Link between Vitamin B12 Deficiency and MS
A recent study, conducted by researchers from Sanford Burnham Prebys, in collaboration with...
Lemtrada
A couple years ago, my second opinion MS doctor mentioned Lemtrada to me. (That was before...